Skip Nav Destination
Issues
15 September 2024
-
Cover Image
Cover Image
The cover shows a section of the tumor center from a patient with pancreatic ductal adenocarcinoma. Multiplex immunohistochemical staining depicts a highly immunogenic tumor microenvironment with high counts of CD3+ (yellow) and CD8+ (green) tumor-infiltrating lymphocytes and decreased counts of CD68+ macrophages (orange). Tumor cells are in cyan and nuclei in blue (DAPI). For details, see the article by Karamitopoulou and colleagues on page 4215 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Issue Sections
CCR Translations
CCR Perspectives in Regulatory Science and Policy
Improving Collection and Analysis of Overall Survival Data
Lisa R. Rodriguez; Nicole J. Gormley; Ruixiao Lu; Anup K. Amatya; George D. Demetri; Keith T. Flaherty; Ruben A. Mesa; Richard Pazdur; Mikkael A. Sekeres; Minghua Shan; Steven Snapinn; Marc R. Theoret; Rukiya Umoja; Jonathon Vallejo; Nicholas J.H. Warren; Qing Xu; Kenneth C. Anderson
Review
Research Briefs: Clinical Trial Brief Reports
A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy
Junji Furuse; Masafumi Ikeda; Makoto Ueno; Masayuki Furukawa; Chigusa Morizane; Tetsuo Takehara; Tomohiro Nishina; Akiko Todaka; Naohiro Okano; Kazuo Hara; Yousuke Nakai; Kazuyoshi Ohkawa; Takashi Sasaki; Kazuya Sugimori; Naoyuki Yokoyama; Kouji Yamamoto
Clinical Trials: Targeted Therapy
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib
Hans Gelderblom; Albiruni A. Razak; Matthew H. Taylor; Todd M. Bauer; Breelyn Wilky; Javier Martin-Broto; Alejandro F. Gonzalez; Piotr Rutkowski; Bartlomiej Szostakowski; Thierry Alcindor; Ramy Saleh; Sofia Genta; Silvia Stacchiotti; Michiel van de Sande; Andrew J. Wagner; Nicholas Bernthal; Lara E. Davis; Jacqueline Vuky; Christopher Tait; Bahar Matin; Supraja Narasimhan; Maitreyi G. Sharma; Rodrigo Ruiz-Soto; Matthew L. Sherman; William D. Tap
A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma
Christian Grommes; Subhiksha Nandakumar; Lauren R. Schaff; Igor Gavrilovic; Thomas J. Kaley; Craig P. Nolan; Jacqueline Stone; Alissa A. Thomas; Sarah S. Tang; Julia Wolfe; Alexis Bozza; Venissala Wongchai; Alisson Hyde; Emma Barrett; Elizabeth A. Lynch; Juli T. Madzsar; Andrew Lin; Anna F. Piotrowski; Elena Pentsova; Jasmine H. Francis; Vaios Hatzoglou; Nikolaus Schultz; Anne S. Reiner; Katherine S. Panageas; Lisa M. DeAngelis; Ingo K. Mellinghoff
Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Logan D. Stone; Benjamin B. Kasten; Shilpa Rao; Manuel. L. Gonzalez; Todd M. Stevens; Diana Lin; William Carroll; Benjamin Greene; Lindsay S. Moore; Andrew Fuson; Sherin James; Yolanda E. Hartman; Susan McCammon; Bharat Panuganti; Lisle M. Nabell; Yufeng Li; Mei Li; Luke Bailey; Eben L. Rosenthal; Harishanker Jeyarajan; Carissa M. Thomas; Jason M. Warram
Clinical Trials: Immunotherapy
Tumor-Localized Interleukin-2 and Interleukin-12 Combine with Radiation Therapy to Safely Potentiate Regression of Advanced Malignant Melanoma in Pet Dogs
Jordan A. Stinson; Matheus Moreno P. Barbosa; Allison Sheen; Noor Momin; Elizabeth Fink; Jordan Hampel; Kim A. Selting; Rebecca L. Kamerer; Keith L. Bailey; Karl D. Wittrup; Timothy M. Fan
Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
Joshua Tobias; Marina Maglakelidze; Zoran Andrić; Dinara Ryspayeva; Iurie Bulat; Ivan Nikolić; Zoran Petrović; Tanuj Chawla; Rajnish Nagarkar; Erika Garner-Spitzer; Christoph C. Zielinski; Leslie Mi Ok Chong; Bonnie Nixon; Nicholas J. Ede; Sharon Yavrom; Michael Kundi; Ursula Wiedermann
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study
Niels Reinmuth; Oscar Juan-Vidal; Dariusz Kowalski; Maciej Bryl; Anna Kryzhanivska; David Vicente; Zsolt Horváth; Gabriella Gálffy; Eszter Csánky; Zsolt Pápai Székely; Ihor Vynnychenko; Jon Armstrong; Tapashi Dalvi; Mingchao Xie; Sonia Iyer; Yashaswi Shrestha; Haiyi Jiang; Igor Bondarenko
Research Briefs: Precision Medicine and Therapeutics
Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort
Xiaopeng Sun; Laura C. Kennedy; Paula I. Gonzalez-Ericsson; Violeta Sanchez; Melinda Sanders; Charles M. Perou; Melissa A. Troester; Justin M. Balko; Sonya A. Reid
Precision Medicine and Imaging
Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
Jordi Martínez-Quintanilla; Débora Cabot; Doménico Sabia; Oriol Arqués; for the PMPnet Group; Jordi Vergés; Irene Chicote; Lana Bijelic; for the PMPnet Group; Laia Cabellos; Anna M. Alcántara; Isabel Ramos; Pedro Barrios; Oriol Crusellas; Lina M. Palacio; for the PMPnet Group; Juan A. Cámara; Jorge Barriuso; for the PMPnet Group; Juan J. Jiménez; Pau Muñoz-Torres; Lara Nonell; Raquel Flores; Enzo Médico; Marcello Guaglio; for the PMPnet Group; Javier Ros; Elena Élez; Josep Tabernero; Omer Aziz; Marcello Deraco; Héctor G. Palmer; for the PMPnet Group; PMPnet Group
SJPedPanel: A Pan-Cancer Gene Panel for Childhood Malignancies to Enhance Cancer Monitoring and Early Detection
Pandurang Kolekar; Vidya Balagopal; Li Dong; Yanling Liu; Scott Foy; Quang Tran; Heather Mulder; Anna L.W. Huskey; Emily Plyler; Zhikai Liang; Jingqun Ma; Joy Nakitandwe; Jiali Gu; Maria Namwanje; Jamie Maciaszek; Debbie Payne-Turner; Saradhi Mallampati; Lu Wang; John Easton; Jeffery M. Klco; Xiaotu Ma
Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Christopher J. Sweeney; Russell Petry; Chang Xu; Merrida Childress; Jie He; David Fabrizio; Ole Gjoerup; Samantha Morley; Timothy Catlett; Zoe J. Assaf; Kobe Yuen; Matthew Wongchenko; Kalpit Shah; Pratyush Gupta; Priti Hegde; Lincoln W. Pasquina; Sanjeev Mariathasan; Ryon P. Graf; Thomas Powles
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial
Antonio Llombart-Cussac; Jose Pérez-García; Fara Brasó-Maristany; Laia Paré; Guillermo Villacampa; Maria Gion; Peter Schmid; Marco Colleoni; Manuel R. Borrego; Patricia Galván; Joel S. Parker; Wesley Buckingham; Charles M. Perou; Patricia Villagrasa; Jose A. Guerrero; Miguel Sampayo-Cordero; Mario Mancino; Aleix Prat; Javier Cortés
Translational Cancer Mechanisms and Therapy
Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps
Alvaro Teijeira; Saray Garasa; Maria C. Ochoa; Sandra Sanchez-Gregorio; Gabriel Gomis; Carlos Luri-Rey; Rafael Martinez-Monge; Beatrice Pinci; Karmele Valencia; Belen Palencia; Benigno Barbés; Elixabet Bolaños; Arantza Azpilikueta; Marina García-Cardosa; Javier Burguete; Iñaki Eguren-Santamaría; Eneko Garate-Soraluze; Pedro Berraondo; Jose L. Perez-Gracia; Carlos E. de Andrea; Maria E. Rodriguez-Ruiz; Ignacio Melero
Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
Ursula Grazini; Aleksandra Markovets; Lucy Ireland; Daniel O’Neill; Benjamin Phillips; Man Xu; Matthias Pfeifer; Tereza Vaclova; Matthew J. Martin; Ludovic Bigot; Luc Friboulet; Ryan Hartmaier; Maria E. Cuomo; Simon T. Barry; Paul D. Smith; Nicolas Floc’h
Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade
Seung Hyuck Jeon; Gihoon You; Junsik Park; Youseung Chung; Kyungjin Park; Hyunjoo Kim; Jaehyoung Jeon; Youngkwang Kim; Woo-Chan Son; Da Som Jeong; Eui-Cheol Shin; Jung-Yun Lee; Dai Hoon Han; Jaeho Jung; Su-Hyung Park
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer
Naoko Iida; Mitsuho Imai; Wataru Okamoto; Takeshi Kato; Taito Esaki; Ken Kato; Yoshito Komatsu; Satoshi Yuki; Toshiki Masuishi; Tomohiro Nishina; Hiromichi Ebi; Hiroya Taniguchi; Norio Nonomura; Yu Sunakawa; Manabu Shiozawa; Kentaro Yamazaki; Shogen Boku; Hideaki Bando; Yuichi Shiraishi; Maki Kobayashi; Hiroki Goto; Akihiro Sato; Satoshi Fujii; Takayuki Yoshino; Yoshiaki Nakamura
Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Yazi Yang; Sen Qin; Mengyu Yang; Ting Wang; Ru Feng; Chunli Zhang; Enrun Zheng; Qinghua Li; Pengyu Xiang; Shangyong Ning; Xiaodong Xu; Xin Zuo; Shuai Zhang; Xiaoya Yun; Xuehong Zhou; Yue Wang; Lin He; Yongfeng Shang; Luyang Sun; Hui Liu
Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer Microenvironment
Maksim A. Chelushkin; Jeroen van Dorp; Sandra van Wilpe; Iris M. Seignette; Jan-Jaap J. Mellema; Maartje Alkemade; Alberto Gil-Jimenez; Dennis Peters; Wim Brugman; Chantal F. Stockem; Erik Hooijberg; Annegien Broeks; Bas W.G. van Rhijn; Laura S. Mertens; Antoine G. van der Heijden; Niven Mehra; Maurits L. van Montfoort; Lodewyk F.A. Wessels; Daniel J. Vis; Michiel S. van der Heijden
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds